GSK partners to trial shingles vaccine in dementia

25 March 2025

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to advance understanding of neurodegeneration with a first-of-its-kind dementia study.

The innovative project aims to use the UK’s health data ecosystem to explore a potential association between GSK’s Shingrix, shingles vaccine, recombinant zoster vaccine (RZV), and a reduced risk of dementia. If successful, this could serve as a blueprint for population level health data research models, reinforcing the UK’s position as a leading destination for scientific research, the company noted.

More than 55 million people worldwide have dementia5, with cases increasing as the global population ages. Research to identify potential opportunities to reduce the risk of dementia is much needed but challenging given the multiple, complex factors which may contribute to the development of the disease6.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK